{"entity":{"id":"duke-street-bio","kind":"company","name":"Duke Street Bio","aka":["Duke Street Bio Ltd"],"tldr":"Duke Street Bio makes DSB2455, a tablet drug that blocks PARP1, a DNA repair enzyme some cancers rely on, while sparing a related enzyme linked to blood-count side effects. It is in an early trial for advanced cancers with DNA repair defects, including cancer that has spread to the brain.","summary":"Duke Street Bio Ltd, at 2 Duke Street, London, develops small molecules against DNA damage repair deficiencies in cancer and immuno-oncology targets; it emerged from stealth in May 2022 discussing PARP1 and PARP7 inhibitor programmes. Its development candidate DSB2455 is a brain-penetrant PARP1 inhibitor that the company says is highly selective over PARP2, whose inhibition is linked to blood toxicity with first-generation PARP inhibitors. The European Medicines Agency approved a clinical trial in September 2024, the first patient was dosed in a phase 1 trial in December 2024, and in June 2025 the FDA granted Fast Track designation for patients with homologous recombination deficient brain metastases from triple-negative breast cancer. The registry lists breast, ovarian, metastatic castration-resistant prostate and pancreatic cancers and brain metastases with homologous recombination deficiency. Its first registered cancer trial, NCT06458712, was posted on ClinicalTrials.gov in June 2024.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://dukestbio.com/"},{"label":"Company news, including the Fast Track designation and first patient dosed","url":"https://dukestbio.com/news/"},{"label":"ClinicalTrials.gov: phase 1 trial of DSB2455 in advanced cancers with homologous recombination deficiency (NCT06458712)","url":"https://clinicaltrials.gov/study/NCT06458712"}],"tags":[],"related":[],"cancers":["tnbc","breast-cancer","ovarian","prostate-mcrpc","pancreatic","secondary-brain-tumours"],"sections":["targeted-therapy"],"technologies":["parp-inhibitor","synthetic-lethality-approaches"],"targets":["parp"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06458712"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated on the company website.","The registry contact domain dukesb.com did not serve a website; the company site is at dukestbio.com.","No financing round was found on the company website; none is recorded.","Company website and news page read on 29 October 2026; the individual releases were read only as summarised on the news page."],"hq":"London","country":"GB","companyType":"biotech","website":"https://dukestbio.com/","stage":"startup","investors":[],"funding":[]},"route":"/companies/duke-street-bio/","neighbours":{"cancer":[{"id":"secondary-brain-tumours","kind":"cancer","name":"Brain metastases (secondary brain tumours)","route":"/cancers/secondary-brain-tumours/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"prostate-mcrpc","kind":"cancer","name":"Metastatic castration-resistant prostate cancer","route":"/cancers/prostate-mcrpc/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"parp-inhibitor","kind":"technology","name":"PARP inhibitors","route":"/technologies/parp-inhibitor/"},{"id":"synthetic-lethality-approaches","kind":"technology","name":"Synthetic lethality approaches","route":"/technologies/synthetic-lethality-approaches/"}],"target":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/"}],"trial":[{"id":"nct06458712","kind":"trial","name":"Study to Assess Safety, Tolerability and Activity of DSB2455 in Participants With Advanced Malignancies","route":"/trials/nct06458712/"}]}}